Search Results
Your search for ,wAs matches 27470 pages
Showing 19551 - 19600ESTRO 2016: Failure to Publish Phase III Radiotherapy Trial Results Exposes Patients to Risks Without Providing Benefits for Others
Although the publication of results of clinical trials carried out in the United States within 12 months of their completion has been mandatory since 2007, a remarkably high number of phase III radiotherapy trials did not do so, according to new research presented at the European Society for...
Genomic Profiling of Orbital and Ocular Adnexal Lymphomas
In a study reported in Modern Pathology, Cani et al used next-generation sequencing to identify actionable mutations in orbital and ocular adnexal lymphomas, finding frequent alterations in MYD88 and chromatin modifiers. Study Details The study involved next-generation sequencing of 36...
Study Links Residential Radon Exposure to Increased Risk of Hematologic Malignancies in Women
A new report published by Teras et al in Environmental Researchfound a statistically significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study...
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
Cancer Screening Using Digital Mammography Alone or With Tomosynthesis in Varying Breast Densities
In a study published by Rafferty et al in JAMA, Elizabeth A. Rafferty, MD, formerly of Massachusetts General Hospital, and colleagues evaluated the screening performance of digital mammography combined with tomosynthesis compared with digital mammography alone for women with varying levels of...
Validation of Rapid Plasma Genotyping for Detecting EGFR and KRAS Mutations in Advanced Lung Cancer
As reported in JAMA Oncology, Sacher et al have prospectively validated a plasma droplet digital polymerase chain reaction (ddPCR) assay for detecting common EGFR and KRAS mutations in patients with advanced nonsquamous non–small cell lung cancer. Study Details The study involved 180...
Poor Understandability of Dense Breast Notifications Sent to Women Following Screening Mammography
In a study published by Kressin et al in JAMA, Nancy R. Kressin, PhD, of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening...
New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk
Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...
Canadian Study Suggests Increased Risk of Cardiac Dysfunction With Trastuzumab-Based Regimens for Breast Cancer
In a Canadian retrospective population-based cohort study reported in the Journal of Clinical Oncology, Thavendiranathan et al found that trastuzumab (Herceptin)-based regimens were associated with an increased risk of treatment-related cardiac dysfunction among women with breast cancer, with an...
ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapy for Breast Cancer
ASCO has adapted a Clinical Care Ontario (CCO) clinical practice guideline on the selection of optimal adjuvant chemotherapy for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancer, as reported in the Journal of Clinical Oncology. The adaptation was based on review by...
Donor Epstein-Barr Virus Status Affects Risk for Graft-vs-Host Disease but Not Survival in Acute Leukemia After HSCT
Positive donor Epstein-Barr virus (EBV) serostatus increases the risk for graft-vs-host disease but does not affect relapse-free or overall survival among patients with acute leukemia receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to a study from the Acute...
Addition of Everolimus to Trastuzumab and Chemotherapy May Benefit Some Patients With Advanced HER2-Positive Breast Cancer
In an analysis of the phase III BOLERO trials reported in the Journal of Clinical Oncology, André et al found that the addition of everolimus (Afinitor) to trastuzumab (Herceptin) and chemotherapy was associated with a progression-free survival benefit in advanced HER2-positive breast cancer ...
Solid Organ Transplant Recipients With Preexisting Malignancies in Remission May Be More Likely to Die, Develop New Cancers
Patients who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer, or develop a new cancer than organ recipients who did not previously have cancer, a new study published by Acuna et al in the journal Transplantation has found. However, the increased...
Stereotactic Body Radiation Therapy May Offer a Higher Cure Rate in Prostate Cancer Than More Traditional Approaches
A 5-year study published by Hannan et al in the European Journal of Cancer showed that stereotactic body radiation therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...
AACR 2016: Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab May Improve Outcomes for Women With HER2-Positive Breast Cancer
Results from the I-SPY 2 TRIAL show that a neoadjuvant therapy combination of the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta) was more beneficial than paclitaxel plus trastuzumab for women with HER2-positive invasive breast cancer, according to research...
Study Finds Radiosensitivity Differences Between Liver Metastases Based on Primary Histology
Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after a year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center...
Amplification of 9p24.1 Associated With Advanced Stage and Poorer Outcome in Classic Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Roemer et al identified PD-L1 (programmed cell death ligand 1) and PD-L2 genetic alterations in patients with classic Hodgkin lymphoma, finding that 9p24.1 amplification was common and associated with advanced-stage disease and poorer...
Advantage of Afatinib vs Gefitinib in First-Line Treatment of EGFR-Mutant NSCLC
The irreversible ErbB family inhibitor afatinib (Gilotrif) was associated with improvement in progression-free survival and time to treatment failure vs the reversible EGFR (epidermal growth factor receptor) inhibitor gefitinib (Iressa) in the first-line treatment of EGFR-mutant non–small...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse event clusters in patients with advanced prostate cancer. The clusters...
Earlier Hospice Enrollment, Avoiding ICU Admissions, and Not Dying in the Hospital Associated With Perceptions of Better End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,” according to a study in...
High-Accuracy Metabolomic Detection of Early-Stage Ovarian Cancer
As reported in Scientific Reports, Gaul and colleagues used high-performance mass spectrometry to interrogate the serum metabolome of patients with early-stage ovarian cancer and healthy controls. They were able to define a linear support vector machine model of 16 metabolites that identified...
Choline Kinase Alpha as Androgen Receptor Chaperone and Prostate Cancer Target
As reported in the Journal of the National Cancer Institute, Asim and colleagues found that choline kinase alpha (CHKA) acts as a chaperone for the androgen receptor (AR) and may serve as a therapeutic target in prostate cancer. CHKA expression was found to be androgen regulated in cell lines,...
Potential Role for HSP70 Peptide Aptamer in Restoring Anticancer Immune Response
Exosomes can activate myeloid-derived suppressor cells via interaction of membrane heat shock protein 70 (HSP70) with Toll-like receptor 2 (TLR2) on the myeloid-derived suppressor cell. As reported in the Journal of the National Cancer Institute, Gobbo and colleagues found that the A8 peptide...
PTK2/FAK as Driver of Radioresistance in HPV-Negative Head and Neck Squamous Cell Carcinoma
As reported in Clinical Cancer Research, Skinner and colleagues used proteomic profiling to identify PTK2/FAK as a driver of radioresistance in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma. Using proteomic and transcriptomic analysis of targetable markers, the...
Potential Biomarker for Carfilzomib Activity in CLL
Carfilzomib (Kyprolis) is active in B-cell neoplasms but exhibits heterogeneous activity in chronic lymphocytic leukemia (CLL) samples. As reported in Clinical Cancer Research, Lamothe and colleagues examined the mechanism by which carfilzomib induces CLL cell death. In studies using CLL patient...
APSHO to Hold Skills Workshops for Advanced Practitioners in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHPO) has announced a series of workshops to be held in cities nationwide during 2016. APSHO, a nonprofit membership organization consisting of nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and...
Quality-of-Life Benefits of Contralateral Prophylactic Mastectomy May Be Too Small to Be Clinically Meaningful
Women diagnosed with breast cancer who chose contralateral prophylactic mastectomy reported improvement in psychosocial well-being and breast satisfaction, but “the magnitude of the effect may be too small to be clinically meaningful,” according to a study in the Journal of Clinical Oncology.1...
City of Hope Awarded $2.5 Million Grant to Launch Nutrition Initiative
Funded by a $2.5 million grant from the Conrad N. Hilton Foundation, City of Hope has launched a 5-year initiative to reduce cancer risk in the Los Angeles area by promoting healthy eating and physical activity, particularly among school children. The long-range plan is to replicate the...
Friends of Cancer Research Encourages FDA to Modernize and Consolidate
“In order to take advantage of today’s advancements in science, drug development, and patient treatment, the U.S. Food and Drug Administration’s (FDA’s) structure needs reorganization to focus its resources and ensure the best outcomes for patients. Friends of Cancer Research (Friends) proposes...
Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
Susannah Koontz, PharmD, BCOP, FHOPA, Named HOPA President-Elect for 2016–2017 Term
Susannah Koontz, PharmD, BCOP, FHOPA, took office as President-Elect of the Hematology/Oncology Pharmacy Association (HOPA) at the recent 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Koontz will serve as President-Elect for the 2016–2017 term and assume the office of...
Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored
Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians.1,2 The guideline recommendations were formulated by a multidisciplinary expert work group and are based...
Leena Gandhi, MD, PhD, Named Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center
New York University (NYU) Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as Director of Thoracic Medical Oncology at its Laura and Isaac Perlmutter Cancer Center. In this new role, Dr. Gandhi will be tasked with building a robust program in lung...
Johns Hopkins Launches Immunotherapy Center With $125 Million Gift
A new institute studying immunology was announced on March 29 at Johns Hopkins by Vice President Joe Biden, Michael R. Bloomberg, and more than a dozen additional supporters of this initiative. Embracing the Vice President’s “moonshot” initiative to cure cancer, the new Bloomberg–Kimmel Institute...
Drug Prices and Value: Finding Middle Ground
The advent of targeted therapies along with complex personalized treatment regimens has added many effective tools to the oncology armamentarium. But progress has a price tag. Although the oncology community needs new drugs, there is growing concern that the price of many newer compounds is...
Timothy J. Eberlein, MD, Elected Chairman of the NCCN Board of Directors
Timothy J. Eberlein, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, has been elected Chairman of the National Comprehensive Cancer Network® (NCCN®) Board of Directors. Dr. Eberlein previously served as Vice Chair of the Board, and succeeds...
ASCO Convenes Obesity Work Group Meeting on Multidisciplinary Collaboration
ASCO recently held a work group meeting with 18 organizations that focused on addressing obesity through multidisciplinary collaboration. The purpose of the meeting was to review current challenges in addressing obesity within the health-care provider communities and identify potential...
2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
Meet W. Charles Penley, MD, FASCO
A Partner at Tennessee Oncology, PLLC, W. Charles Penley, MD, FASCO, has been an ASCO member since 1988. He has served on the Conquer Cancer Foundation Board of Directors since 2005 and currently holds the role of Immediate Past Chair. What led you to oncology? WCP: While it may sound silly to say ...
AACR 2016: Genomic Variants May Influence Risk for Breast Cancer After Chest Radiotherapy to Treat Childhood Cancer
Among females who received radiotherapy to the chest as part of treatment for a childhood cancer, those who had either of two specific genetic variants were at significantly higher risk of developing breast cancer later in life, according to research presented by Morton et al at the 2016 AACR...
AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients
A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...
KIR3DL1 and HLA-B Allele Combinations May Impact Response to Treatment in Neuroblastoma
In a study reported in the Journal of Clinical Oncology, Forlenza et al found that noninteracting KIR3DL1 and HLA-B subtypes were associated with better response to anti-GD2 antibody treatment in neuroblastoma. Study Details Treatment of neuroblastoma with anti-GD2 monoclonal antibody (eg, the...
AACR 2016: Nivolumab Improved Survival for Patients With Head and Neck Squamous Cell Carcinoma
For the latest information on CheckMate-141, click here, here, or here. Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with...
Adjuvant Trastuzumab May Be Insufficiently Used in Older Women With Breast Cancer
Reeder-Hayes et al found that adjuvant trastuzumab (Herceptin) may be underused in older women with early-stage HER2-positive breast cancer and reported their study results in the Journal of Clinical Oncology. Adjuvant trastuzumab also was used less often in black women than in white women. Rates...
Adding Rituximab to Dose-Dense Chemotherapy May Be of Benefit in Burkitt Lymphoma
In a French phase III trial reported in The Lancet, Ribrag et al showed that adding rituximab (Rituxan) to dose-dense chemotherapy improved event-free survival among adults with Burkitt lymphoma. Study Details In the open-label trial, 260 patients were randomized between October 2004 and...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
